First AD

Second AD

Navigating treatment strategies for patients with multi-refractory CLL: CAR-T, ASCT, and PI3K Inhibitors

Video content above is prompted by the following:

Briefly mention additional treatment options in R/R CLL:

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies

Panelists discuss how various additional treatment options for relapsed/refractory chronic lymphocytic leukemia (CLL) are considered, including CAR-T cell therapy, immunomodulatory drugs like lenalidomide, chemoimmunotherapy regimens, and other emerging therapies, highlighting their potential roles in the evolving treatment landscape.

The Current Treatment Landscape for R/R CLL

Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL 